Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma

Rectal Cancer Clinical Trial

Official title:

Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00353457
• Other study ID #: 803437
• Secondary ID: UPCC 09204
• Status: Terminated
• Phase: Phase 2
• Start date: February 2006
• Est. completion date: June 2011

Study information

• Verified date: April 2020
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II study of induction chemotherapy (capecitabine, oxaliplatin and cetuximab (erbitux)) followed by capecitabine, oxaliplatin, cetuximab and radiotherapy followed by surgery followed by adjuvant capecitabine, oxaliplatin and cetuximab for locally advanced resectable rectal cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed nonmetastatic, measurable, locally advanced (T3 or T4) rectal adenocarcinoma

• If available, tumor tissue must be sent for investigational immunohistochemical evaluations of EGFR status

• The distal border of the tumor must be at or below the peritoneal reflection (defined a with 12 cm of the anal verge by proctoscopy)

• Transmural penetration of the tumor demonstrated by CT + endorectal ultrasound or MRI

• ECOG PS 0-2

• No prior chemotherapy, biologic therapy or radiation therapy

• Age >= 18 years old

• Laboratory values: ANC >= 1500/mm3; Platelets >= 100,000/mm3; Hgb >= 9 g/dL; Estimated CrCl > 50 mL/min; Serum bilirubin <= 1.5 x ULN; AST and ALT <= 3.0 x ULN; Negative proteinuria based on dip stick reading

• Patients must either be not of child bearing potential or have a negative pregnancy test upon study enrollment. Patients must agree to continue contraception for 30 days from the date of the last study drug administration.

Exclusion Criteria:

• Pregnant or lactating woman. Women of childbearing potential with either a positive or no pregnancy test upon study enrollment. Women/men of childbearing potential not using a reliable and appropriate contraceptive method. Patients must agree to continue contraception for 30 days from the date of the last study administration.

• Life expectancy < 3 months

• Serious, uncontrolled, concurrent infection(s)

• Concurrent use of chemotherapy not indicated in the study protocol or any other investigational agents and patients who have received investigational drugs < 4 weeks prior to randomization.

• Prior therapy which specifically and directly targets the EGFR pathway.

• Prior severe infusion reaction to a monoclonal antibody

• Any prior therapy with Oxaliplatin

• Prior pelvic irradiation for any reason

• Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil or known DPD deficiency

• Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer

• Participation in any investigational drug study within 4 weeks preceding the start of the study treatment

• Major surgery within 4 weeks of the study treatment, without complete recovery

• Known, existing uncontrolled coagulopathy

• Unwillingness to give written informed consent

• Unwillingness to participate or inability to comply with the protocol for the duration of the study

• Known allergy or hypersensitivity to platinum-containing drugs

• Peripheral sensory neuropathy with functional impairment

• Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung

• Pleural effusions or ascites that causes respiratory compromise

• Acute hepatitis or known HIV

• Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study: uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with anti-hypertensive regimen; unstable angina pectoris; symptomatic congestive heart failure; myocardial infarction < 6 months prior to randomization; serious uncontrolled cardiac arrhythmia; uncontrolled diabetes; active or uncontrolled infection; impairment of gastrointestinal function or GI disease that may significantly alter the absorption of Capecitabine.

• Evidence of CNS metastases or history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.

Related Conditions & MeSH terms

• Adenocarcinoma
• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• Capecitabine, Oxaliplatin and Cetuximab
Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8

Radiation:
• Radiation
45 Gy in 25 fractions, 3-fraction boost 5.4 Gy

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania	Bristol-Myers Squibb, Roche Pharma AG

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathologic complete response		After neoadjuvant treatment
Secondary	Sphincter function		After surgery
Secondary	Type of surgery		At time of surgery
Secondary	Disease free survival		From time of study entry until first documented relapse